



Hexosamines, insulin resistance, and the complications of diabetes: current status

Maria G. Buse

AJP - Endo 290:1-8, 2006. doi:10.1152/ajpendo.00329.2005

You might find this additional information useful...

This article cites 89 articles, 70 of which you can access free at:

<http://ajpendo.physiology.org/cgi/content/full/290/1/E1#BIBL>

Medline items on this article's topics can be found at <http://highwire.stanford.edu/lists/artbytopic.dtl> on the following topics:

- Pharmacology .. Plasminogen Activators
- Immunology .. Transcription Factors
- Biochemistry .. Plasminogen
- Biophysics .. Sarcoplasmic Reticulum
- Oncology .. Insulin Resistance
- Medicine .. Diabetes

Updated information and services including high-resolution figures, can be found at:

<http://ajpendo.physiology.org/cgi/content/full/290/1/E1>

Additional material and information about *AJP - Endocrinology and Metabolism* can be found at:

<http://www.the-aps.org/publications/ajpendo>

This information is current as of April 18, 2006 .

Hexosamines, insulin resistance, and the complications of diabetes: current status

Maria G. Buse

Department of Medicine, Division of Endocrinology, Diabetes and Medical Genetics, Medical University of South Carolina, Charleston, South Carolina

Buse, Maria G. Hexosamines, insulin resistance, and the complications of diabetes: current status. *Am J Physiol Endocrinol Metab* 290: E1–E8, 2006; doi:10.1152/ajpendo.00329.2005.—The hexosamine biosynthesis pathway (HBP) is a relatively minor branch of glycolysis. Fructose 6-phosphate is converted to glucosamine 6-phosphate, catalyzed by the first and rate-limiting enzyme glutamine:fructose-6-phosphate amidotransferase (GFAT). The major end product is UDP-*N*-acetylglucosamine (UDP-GlcNAc). Along with other amino sugars generated by HBP, it provides essential building blocks for glycosyl side chains, of proteins and lipids. UDP-GlcNAc regulates flux through HBP by regulating GFAT activity and is the obligatory substrate of *O*-GlcNAc transferase. The latter is a cytosolic and nuclear enzyme that catalyzes a reversible, posttranslational protein modification, transferring GlcNAc in *O*-linkage (*O*-GlcNAc) to specific serine/threonine residues of proteins. The metabolic effects of increased flux through HBP are thought to be mediated by increasing *O*-GlcNAcylation. Several investigators proposed that HBP functions as a cellular nutrient sensor and plays a role in the development of insulin resistance and the vascular complications of diabetes. Increased flux through HBP is required and sufficient for some of the metabolic effects of sustained, increased glucose flux, which promotes the complications of diabetes, e.g., diminished expression of sarcoplasmic reticulum Ca²⁺-ATPase in cardiomyocytes and induction of TGF- β and plasminogen activator inhibitor-1 in vascular smooth muscle cells, mesangial cells, and aortic endothelial cells. The mechanism was consistent with enhanced *O*-GlcNAcylation of certain transcription factors. The role of HBP in the development of insulin resistance has been controversial. There are numerous papers showing a correlation between increased flux through HBP and insulin resistance; however, the causal relationship has not been established. More recent experiments in mice overexpressing GFAT in muscle and adipose tissue or exclusively in fat cells suggest that the latter develop *in vivo* insulin resistance via cross talk between fat cells and muscle. Although the relationship between HBP and insulin resistance may be quite complex, it clearly deserves further study in concert with its role in the complications of diabetes.

hexosamine biosynthesis pathway; *N*-acetylglucosamine; *O*-linked *N*-acetylglucosamine; modification of proteins

INSULIN RESISTANCE IS A HALLMARK of type 2 diabetes, of uncontrolled type 1 diabetes, and of obesity and the metabolic syndrome (91) and is associated with numerous other conditions, such as cystic fibrosis, uremia, septicemia, glucocorticoid excess, polycystic ovary syndrome, etc. Clinically, insulin resistance is defined as the reduced ability of insulin to lower plasma glucose, which reflects in great part impaired insulin-stimulated glucose transport into tissues, which express the insulin-responsive glucose transporter GLUT4 (skeletal and heart muscle and adipocytes). Except for a few rare conditions, the major defect(s) is downstream of insulin's binding to its receptors. Type 2 diabetes is a polygenic disease, and several recent, excellent reviews discuss the insulin receptor signaling cascade and proposed mechanisms of impaired signal transduction in insulin resistance (57, 69, 70, 72). The propensity to insulin resistance is likely genetically determined (79); however, the expression of the phenotype is modulated by various factors, including diet, exercise, and aging.

Sustained hyperglycemia causes insulin resistance in humans (89) and in animal models (67), which leads to the concept of "glucose toxicity." The latter accounts for the insulin resistance in uncontrolled type 1 diabetes (89). Similarly, sustained elevations of circulatory nonesterified fatty acids (NEFA) also induce insulin resistance ("lipotoxicity"). Thus insulin resistance may represent an adaptive mechanism that may serve to protect cells from the deleterious effects of excessive nutrient flux, such as oxidative stress. This would imply the existence of cellular biochemical sensors, which monitor the flux of nutrients. McGarry (47) first identified malonyl-CoA as a biochemical sensor that regulates the switch from fatty acid to glucose oxidation in the liver. Several laboratories have proposed that flux through the hexosamine synthesis pathway (HSP) may function as a cellular nutrient sensor and play a role in the development of insulin resistance and the vascular complications of diabetes (4, 5, 24, 44, 66). This review addresses the experimental evidence that supports and questions this hypothesis and the proposed mechanisms by which the HSP may exert these effects.

A role for excess glucose flux via HSP in insulin resistance was first proposed by Marshall et al. in 1991 (43) on the basis

Address for reprint requests and other correspondence: M. G. Buse, Dept. of Medicine, Div. of Endocrinology, Diabetes and Medical Genetics, Medical University of South Carolina, Charleston, SC 29425 (e-mail: busemg@musc.edu).

of experiments using isolated rat adipocytes. In this system, preexposure of the cells to insulin and high glucose act synergistically to induce resistance of glucose transport to subsequent acute stimulation by insulin. The insulin resistance develops only if a complete amino acid mixture or glutamine is present in the medium during preincubation with high glucose and insulin. The requirement for glutamine suggested the involvement of the HSP (43).

The HSP is a relatively minor branch of the glycolytic pathway, encompassing ~3% of total glucose utilized (43) (Fig. 1). Entry into the HSP is catalyzed by the first and rate-limiting enzyme glutamine:fructose 6-phosphate (F-6-P) amidotransferase (GFAT), which converts F-6-P and glutamine to glucosamine 6-phosphate (GlcN-6-P) and glutamate. Subsequent steps metabolize GlcN-6-P to UDP-*N*-acetylglucosamine (UDP-GlcNAc), UDP-*N*-acetylgalactosamine (UDP-GalNAc), and CMP-sialic acid, essential building blocks of the glycosyl side chains of glycoproteins, glycolipids, proteoglycans, and gangliosides. UDP-GlcNAc is of particular interest because 1) quantitatively it is the major end product of the HSP; 2) it is an allosteric feedback inhibitor of GFAT, which regulates glucose entry into the pathway; and 3) it is the obligatory substrate of *O*-GlcNAc transferase (OGT). The latter is a cytosolic and nuclear enzyme that catalyzes a reversible posttranslational protein modification, whereby GlcNAc is transferred in *O*-linkage to specific serine/threonine residues of numerous proteins (37, 42). The sites of *O*-GlcNAc modification (*O*-GlcNAcylation) are often identical or adjacent to known phosphorylation sites, suggesting a regulatory function (14). Functional significance of *O*-GlcNAcylation has been reported for several proteins (85), including the transcription factors Sp1 (16, 26, 65, 78, 86), c-myc (34), cAMP response element-binding protein (40), signal transducer and activator of transcription-5 (21), and pancreatic duodenal homeobox-1 (18), as well as cytosolic and nuclear enzymes, e.g., glycogen synthase (54, 55) and RNA polymerase II (14). Of particular interest in the context of insulin resistance is that insulin receptor substrates (IRS)-1 and -2 (1, 17, 56, 77), and

probably also GLUT4 (8), are subject to *O*-GlcNAcylation. Although the *O*-GlcNAc modification of IRS-1 in the references cited was based on immunological methods, an *O*-GlcNAcylation site on IRS-1 was recently identified by mass spectrometry (2). The reversible, *O*-GlcNAc modification of proteins has been suggested by many investigators as a mechanism by which increased HSP activity could cause insulin resistance and the complications of diabetes.

There is considerable evidence indicating that increased activity of the HSP can cause insulin resistance in cell culture models and in rodents *in vivo*. In the model mentioned above, where sustained exposure to high glucose in the presence of insulin caused insulin resistance in adipocytes, treatment of the cells with inhibitors of GFAT activity prevented this effect. Furthermore, glucosamine (GlcN), which enters the HSP bypassing GFAT, also caused insulin resistance but at much lower doses than glucose. The effect of GlcN infusions on the development of insulin resistance in rodents undergoing insulin clamp studies has been extensively studied (3, 56, 68). Rossetti et al. reported in 1995 that infusion of GlcN increased the concentrations of UDP-GlcNAc in muscle and markedly decreased insulin-stimulated total body glucose utilization in healthy controls, but not in diabetic rats, which were already insulin resistant (68). Previous studies had demonstrated that *in vitro* treatment of isolated muscles with GlcN inhibited the insulin response of glucose transport without affecting insulin receptor and GLUT4 expression (62). Sustained hyperglycemia, which causes insulin resistance, also increased UDP-*N*-acetylhexosamine (HexNAc) concentrations in muscles (63). The insulin resistance that develops in rats infused with lipid emulsions is also associated with increased UDP-GlcNAc in muscle, presumably reflecting impaired glycolytic flux distal to F-6-P, resulting in increased flux via HSP (28). On the basis of various clamp studies, Hawkins and colleagues (27, 28) proposed that the UDP-GlcNAc concentration in skeletal muscle may modulate the insulin responsiveness of glucose transport. However, this conclusion has been questioned by Choi et al. (12), who found that increasing circulating free fatty acids induces peripheral insulin resistance without concomitant increases in the concentrations of UDP-GlcNAc or UDP-GalNAc in muscle.

Mice overexpressing GLUT1 in muscle exhibit chronically increased muscle glucose flux, increased muscle glycogen, and mild fasting hypoglycemia without significant changes in circulating insulin or glucagon. Insulin fails to stimulate glucose transport in the insulin-resistant muscles *in vitro*, although GLUT4 expression is unchanged.

Other stimuli that normally stimulate glucose transport, e.g., IGF-I, hypoxia, and contractile activity, are also ineffective in GLUT1-overexpressing mice (22). UDP-HexNAc concentrations and GFAT activity are markedly increased in these muscles (9), as well as the *O*-GlcNAc modification of numerous membrane-associated proteins, which may include GLUT4 and/or proteins associated with GLUT4 (8), suggesting but not proving that the HSP may be involved. Other suggestive correlations include that GFAT activity and UDP-HexNAc concentrations are increased in leptin-deficient, insulin-resistant *ob/ob* mice (7), whereas at the other end of the spectrum UDP-HexNAc concentrations are reduced in muscles of growth hormone-deficient rats (64) and in rats with chronic caloric restriction and enhanced insulin sensitivity (20).




Fig. 1. A simplified schematic representation of the hexosamine biosynthetic pathway. Black arrows indicate that flux through the pathway can be increased by accelerating glucose entry or by inhibiting glycolysis distal to fructose 6-phosphate. GFAT, glutamine:fructose-6-phosphate amidotransferase; Glc-6P, glucose 6-phosphate (G-6-P); Fru-6P, fructose 6-phosphate (F-6-P); GlcN, glucosamine; GlcNAc, *N*-acetylglucosamine; ER, endoplasmic reticulum (adapted from Ref. 2).

In vitro studies from Holloszy's laboratory [Kawanaka et al. (35)] make a strong argument against the role of the HSP in glucose/insulin-induced insulin resistance in muscle. In this model, isolated epitrochlearis muscles were incubated for 5 h with high doses of insulin and a high concentration of either glucose (36 mM) or normal glucose (5 mM) before glucose transport was measured. The latter was reduced by 50% in the high-glucose-treated group, and this was unchanged when the high-glucose-induced accumulation of UDP-HexNAc was prevented by inclusion of a GFAT inhibitor. [Note that the same GFAT inhibitor reversed glucose-induced insulin resistance in earlier studies in adipocytes (43).] Incubation with actinomycin-D or cycloheximide or activation of AMP-activated protein kinase each reversed the high-glucose-induced insulin resistance in the muscle, suggesting that a rapidly turning-over protein and dephosphorylation of a transcription factor may be involved (35). In a follow-up study [Han et al. (25)], they provided evidence that exposure to GlcN or to high glucose causes insulin resistance in skeletal muscle by different mechanisms. We (49, 50) reached similar conclusions in 3T3-L1 adipocytes.

Transgenic mice overexpressing GFAT in skeletal muscle and adipocytes develop peripheral insulin resistance as they age, as determined by euglycemic insulin clamp studies. GLUT4 expression in muscle is unchanged, and the insulin resistance likely represents defective translocation of GLUT4 to the muscle cell membrane or a defect in docking and/or incorporation of GLUT4 into the plasmalemma of muscle in vivo (15, 30). However, upon in vitro testing, the insulin response of glucose transport of isolated muscles from GFAT-overexpressing, in vivo insulin-resistant mice is identical to that of wild-type mice (29). When GFAT was overexpressed only in adipocytes, the mice developed fat cell hypertrophy, increased plasma leptin, and decreased adiponectin, as well as total body insulin resistance by insulin clamp studies. The authors concluded that the in vivo insulin resistance that develops in mice overexpressing GFAT in adipocytes alone (29) or in adipocytes and in muscle cells likely reflects cross talk between adipocytes and skeletal muscle and may be mediated by the decreased circulating adiponectin levels in GFAT-overexpressing mice (29). Note the differences in phenotype between the transgenic mice overexpressing GLUT1 in muscle and those overexpressing GFAT in muscle and adipose tissue. Although the mouse with chronically increased glucose flux into muscle develops profound resistance to insulin in vitro (22), the GFAT-overexpressing mouse manifests insulin resistance only in vivo, not in vitro. It should be noted, however, that GFAT overexpression in these transgenic models was relatively low.

In a preliminary report, Obici (52) presented data on transgenic mice overexpressing GFAT only in skeletal muscle, developed in collaboration with Rossetti's laboratory. Contrary to their expectations, when studied by the euglycemic insulin clamp technique, there were no significant differences either in whole body glucose utilization or in hepatic glucose output between transgenic and control mice, although GFAT expression was approximately threefold higher in transgenic muscle, UDP-GlcNAc concentration was increased >20%, and *O*-GlcNAc modification of proteins was also increased in transgenic muscles compared with controls. Circulating leptin was unchanged, but leptin expression in muscles appeared to be

increased. Insulin-stimulated 2-deoxyglucose transport into muscle appeared to be slightly blunted in the transgenic mice (52). The lack of an effect on muscle insulin resistance is in marked contrast with previous observations from this laboratory, where hexosamine flux in muscle was increased during relatively short (hours to days) time periods by general infusion of GlcN, glucose, or other nutrients (27, 28, 53, 61, 68).

The validity of using GlcN infusions to model the role of HSP in insulin resistance has been questioned (31, 49, 50, 76). GlcN is present at very low concentrations in plasma, and its production in the cell is limited by feedback inhibition of GFAT activity by UDP-GlcNAc. When extracellular GlcN is increased by infusions of GlcN, GlcN-6-PO₄ accumulates markedly in cells [700- to 500-fold in heart and skeletal muscle, respectively (76)], whereas this compound is nearly undetectable in cells exposed to glucose alone, suggesting that UDP-HexNAc generation from GlcN is limited at a step distal to hexokinase (50). The accumulation of GlcN-6-PO₄ depletes intracellular ATP, which can cause spurious insulin resistance by blocking early insulin receptor signaling. This has been clearly demonstrated in 3T3-L1 adipocytes incubated with high concentrations of insulin and GlcN without glucose (31). However, under milder conditions, ATP depletion due to GlcN treatment is much reduced and does not account for GlcN-induced insulin resistance. Nevertheless, there are clear differences between the metabolic effects of high glucose and GlcN in fat cells and in muscle, although both models can induce insulin resistance and promote the *O*-GlcNAc modification of certain proteins (25, 49, 50). Therefore, results using GlcN to model the role of the HBP in the development of insulin resistance need to be interpreted with caution. In support of this, we have conducted gene array analysis on 3T3-L1 adipocytes incubated under various conditions that elicit (or do not) insulin resistance. Although sustained 8-h exposure to high (25 mM) glucose plus low-dose insulin (0.6 nM) generated similar insulin resistance to incubation with 5 mM glucose plus 2.5 mM GlcN plus low-dose insulin, GlcN-exposed cells exhibited marked changes in the expression of numerous genes that were specific to GlcN exposure (unpublished data with the Bioinformatics group at Hoffmann-La Roche: Rosinski J, So WV, and Martin M), supporting the concept that GlcN exerts numerous effects that are not duplicated by increased glucose flux via HSP.

Regardless of the mode of action of GlcN, increased glucose flux via the HSP is associated with insulin resistance, at least in experimental models. What is the mechanism? In transgenic mice overexpressing GFAT in muscle and fat, in vivo insulin resistance was associated with impaired translocation of GLUT4 to the muscle plasma membrane (15). The expression of GLUT1 and GLUT4 was unchanged. Similarly, in 3T3-L1 adipocytes, insulin-resistant glucose transport, which developed following preincubation in high glucose or low glucose plus GlcN (provided that a low concentration of insulin was present), was not accompanied by changes in GLUT4 or GLUT1 expression (50). However, in one paper studying a similar model, it was believed that the insulin resistance of glucose transport reflected the accelerated degradation of GLUT4 (73). In the 3T3-L1 adipocyte model where insulin resistance was achieved by preincubation with GlcN, a defect in GLUT4 translocation was clearly demonstrated (50). However, in the model where the same degree of insulin resistance

developed following exposure to high glucose in the presence of insulin, GLUT4 translocation was less compromised (50, 51), suggesting a second defect, impaired docking or fusion of the GLUT4-carrying vesicle with the plasma membrane or decreased intrinsic activity of GLUT4. It is becoming increasingly evident that the “translocation” of GLUT4 to the plasma membrane occurs in various stages, which respond to different regulatory signals that encompass 1) the movement of GLUT4-containing vehicles toward the plasma membrane, which does not require Akt activation, and 2) docking and fusion with the plasma membrane, which does (32, 75). Our data are consistent with the concept that the insulin resistance elicited by glucose toxicity involves in great part a block at the docking/fusion step (51). This is supported by the observation that the insulin-regulated trafficking of Munc18c, a syntaxin 4-binding protein that regulates the docking/fusion step, is disrupted in cells with high glucose or GlcN-induced insulin resistance (51). Note that Munc18c is subject to modification on serine/threonine residues by *O*-GlcNAc, the end product of HSP (10).

Which steps of the insulin-signaling cascade are compromised in insulin resistance? There is consensus that insulin resistance is a manifestation of complex alterations in signal transduction between the activated insulin receptor and its final target, (reviewed in Refs. 57 and 69–72). Most investigators have found inhibition of the proximal insulin-signaling cascade to be associated with insulin resistance. In models of diabetes associated with obesity and lipotoxicity, the predominant block appears to be at the insulin-stimulated activation of PI 3-kinase, due to its reduced association with IRS-1 and -2. This, in turn, represents the reduced insulin-stimulated activation (tyrosine phosphorylation) of IRS, which reflects IRS phosphorylation on specific serine and threonine residues. The involvement of protein kinase C, specifically PKC θ , has been implicated in this process, although other mechanisms, e.g., cytokines, NF- κ B, and stress-activated MAP kinases (particularly p38) contribute (71). On the other hand, in high glucose-induced insulin resistance, in muscle and fat in vitro, insulin activation of IRS-1-associated PI 3-kinase was unaffected, and the block in signal transduction appeared to be located downstream of PI 3-kinase, at the level of Akt activation (39, 49). Alternatively, in a model of short preincubation of muscles with high glucose and insulin, no defect in the signaling cascade was detected, the participation of the HSP was excluded, and the induction of a rapidly turning-over protein was postulated as the cause of insulin resistance (35). Clearly, different experimental models can block insulin signaling at different sites, with insulin-resistant glucose transport being the common outcome. If the HSP contributes to insulin resistance, its role in the different models and cells will have to be defined.

How does increased flux through the HSP cause insulin resistance or participate in the development of the complications of diabetes? The accumulation of UDP-GlcNAc in tissues promotes the *O*-GlcNAc modification on serine/threonine residues of selected proteins, and this process is believed to mediate the effects of HSP. Increased glucose flux into cells and via HSP does promote *O*-GlcNAcylation. The process is catalyzed by the cytosolic/nuclear enzyme OGT, which is responsive to UDP-GlcNAc concentrations in the physiological range (37, 42). UDP-GlcNAc regulates OGT in part by mass action, i.e., by the availability of substrate, and in part allosterically in a protein substrate-selective manner (38, 84).

Numerous investigators have reported increased *O*-GlcNAc modification of proteins (demonstrated immunologically), in tissue culture or in experimental animals, under conditions of insulin resistance where glucose flux into cells was chronically increased or after exposure to GlcN or in cells overexpressing GFAT (8, 44, 56, 66, 90). However, the proteins were only rarely identified, and a causal connection was not established. More recently, more direct evidence has emerged. The enzyme that removes the *O*-GlcNAc modification from serine/threonine is *O*-GlcNAcase, which has been cloned (19, 83). A pharmacological agent that is a competitive inhibitor of *O*-GlcNAcase has been developed [*O*-(2-acetamido-2-deoxy-D-glucopyranosylidene)-amino-*N*-phenylcarbamate (PUGNAC) (23). When 3T3-L1 adipocytes are incubated with PUGNAC, the removal of *O*-GlcNAc from proteins is inhibited, and the cells develop insulin-resistant glucose transport as well as inhibition of insulin-stimulated Akt activation. Although IRS-1 and -2 are modified by *O*-GlcNAc, their insulin-stimulated tyrosine phosphorylation was not affected (77). Thus PUGNAC reproduces the same scenario as that observed in these cells after incubation in high glucose plus low-dose insulin (49, 50).

Transgenic mice with modest overexpression of OGT in skeletal muscle and in adipocytes develop hyperinsulinemia, insulin resistance (as assessed by euglycemic insulin clamp studies), and hyperleptinemia, without changes in body weight, glycemia, or GLUT4 expression in muscle (45), a phenotype that is similar to that achieved by overexpressing GFAT in muscle and fat tissue (15, 30).

A link between the *O*-GlcNAc modification and complications of diabetes has been demonstrated in neonatal cardiomyocytes in studies of diabetic cardiomyopathy. When cardiomyocytes are incubated in high (25 mM) vs. low (5 mM) glucose, abnormalities in Ca²⁺ cycling develop in high glucose-treated cells that are attributable to reduced mRNA and protein expression of sarcoplasmic reticulum Ca²⁺-ATPase (SERCA2a). Ca²⁺ cycling and SERCA2a expression were restored toward normal by treating high glucose-exposed cells with an adenovirus expressing *O*-GlcNAcase (13). The regulation was at the transcriptional level, as demonstrated by parallel regulation of two transcription factors that regulate SERCA2a expression. Thus, in the neonatal cardiomyocyte model, overexpression of an enzyme that removes *O*-GlcNAc from proteins reversed the deleterious effects caused by pre-exposure to high glucose.

We carried out similar experiments in 3T3-L1 adipocytes, where we tried to reverse or mitigate high glucose/insulin-induced insulin resistance by adenovirus-mediated *O*-GlcNAcase overexpression (6). Preexposure to high glucose plus low-dose insulin decreased the maximal and half-maximal insulin response of glucose transport by 40–50% compared with cells preincubated in 5 mM glucose. This downregulation was similar in cells infected with *O*-GlcNAcase adenovirus or empty virus. Impaired insulin-stimulated Akt activation in insulin-resistant cells was also unaffected by *O*-GlcNAcase overexpression. In postnuclear supernatants of infected cells, *O*-GlcNAcase enzyme activity and protein expression were increased fivefold, and *O*-GlcNAc-modified proteins were decreased. However, in isolated nuclei, no significant increase in *O*-GlcNAcase activity was detected, suggesting poor nuclear access of the recombinant enzyme (6), confirming similar

observations in COS-7 cells (19). The lack of effect of *O*-GlcNAcase overexpression in preventing or mitigating insulin resistance may reflect a lack of participation of this pathway in the development of insulin resistance. However, if increased protein *O*-GlcNAcylation plays a causative role in the development of insulin resistance, it likely involves transcriptional regulation. A factor that may affect *O*-GlcNAcylation and the development of insulin resistance may be *O*-GlcNAcase transport into the nucleus. This is of particular interest in view of increasing evidence indicating that both OGT and *O*-GlcNAcase are regulated by posttranscriptional modification and by alternative splicing and that they interact with numerous binding partners (19, 83, 84). Histones and transcription factors are regulated by a number of posttranslational modifications, which in turn regulate gene expression. These modifications occur in large multi-subunit complexes. The corepressor Sim3A, known to recruit histone deacetylase (HDAC), also recruits OGT via its TPR domain to specific genes (87). Thus OGT and HDAC may act in concert to repress transcription. On the other hand, *O*-GlcNAcase has been recently shown to be a bifunctional protein, with the NH₂ terminus expressing the *O*-GlcNAcase activity and the COOH terminus acting as a histone acetyltransferase (HAT) *in vitro*, with a typical HAT domain that has both active and inactive states (74). Thus *O*-GlcNAcase may function to reduce the state of glycosylation of transcriptional activators while increasing the acetylation of histones, to allow for the concerted activation of eukaryotic gene transcription. The factors regulating traffic of *O*-GlcNAcase in and out of the nucleus and its interaction with specific genes deserve further study.

There is a remarkable, evolving consensus regarding the role of the HSP in the pathogenesis of the renal/vascular complications of diabetes. The accumulation of extracellular matrix in the glomerulus is an early and hallmark event in the development of diabetic glomerulosclerosis, and it has been long known that sustained hyperglycemia promotes its development in patients and in experimental models of diabetes. Different mechanisms have been implicated in the hyperglycemia-induced increased matrix production, including activation of the polyol pathway, increased nonenzymatic glycosylation end products, and high glucose-induced stimulation of PKC (36). A role for the HSP in the effects of hyperglycemia on growth factor gene expression in vascular smooth muscle cells was first proposed by McClain et al. (46) in 1992. More recently, it has become evident that transforming growth factor- β (TGF- β) synthesis is required for the effects of high glucose (92); the glucose effect was mitigated by treating cells with anti-TGF- β antibody (92) or with antisense TGF- β 1 oligonucleotide (36). Furthermore, glucosamine reproduced the effect of glucose on TGF- β 1 induction, albeit with greater potency, and blocking GFAT activity with antisense GFAT oligonucleotide or with a chemical inhibitor of GFAT activity inhibited high glucose/GlcN stimulation of TGF- β 1 synthesis (36). Overexpressing GFAT in mesangial cells induced TGF- β 1 and fibronectin expression in cells incubated in 5 mM glucose (81). Thus TGF- β 1 expression is dependent, at least in part, on HSP activity.

An elegant recent paper addresses the mechanism by which increased HSP activity may stimulate TGF- β 1 expression. The promoter of TGF- β 1 (–1013 to –1002 region) contains a sequence that is highly homologous to glucose response ele-

ments (GREs) previously identified in genes of glucose-regulated proteins such as liver pyruvate kinase. GREs bind to upstream stimulatory factors USF-1 and -2, which enhance TGF- β 1 expression. Incubation with high glucose or increasing flux through the HSP by overexpressing GFAT increased the expression of USF-1 and -2, although the proteins themselves were not *O*-GlcNAc modified. Increased USF expression and DNA-binding activity led to upregulation of TGF- β 1 promoter activity (80). Note, however, that the GRE domain is not the only site at which TGF- β 1 is regulated. There are two activator protein-1 binding sites on the promoter (–448/–412 and –371/–363, respectively) that are regulated by PKC- and MAP kinase-dependent pathways, which are also involved in glucose-mediated activation of TGF- β 1 expression (80).

Hyperglycemia stimulates the expression of plasminogen activator inhibitor 1 (PAI-1) in vascular smooth muscle cells (11), aortic endothelial cells (16), and mesangial cells (33), and this is thought to be an important factor in the development of vascular disease in diabetes. The impetus for looking for a role of the HSP in glucose-stimulated expression of PAI-1 was the observation that high glucose exerted its effect by activating two adjacent Sp1 binding sites in the NH₂-terminal flanking region of the PAI-1 (–85–42) promoter (11). Sp1 was the first transcription factor identified as an *O*-GlcNAc-modified protein; it has multiple *O*-GlcNAc modification sites, and its phosphorylation on Ser/Thr is inversely proportional to its *O*-GlcNAc modification (26, 65, 86). Furthermore, in addition to regulating the expression of PAI-1, Sp1 has been implicated in the regulation of expression of several glucose-regulated genes, e.g., acetyl-CoA carboxylase, leptin, fatty acid synthase, and ATP citrate lyase (reviewed in Ref. 19). Furthermore, the *O*-GlcNAc modification of Sp1 increases with increasing ambient glucose or with insulin (19). Two laboratories have now shown the involvement of the HSP in PAI-1 activation of expression. Incubation in high glucose or with GlcN or overexpression of GFAT enhanced the activation of the PAI-1 promoter, as well as stimulating TGF- β expression in mesangial cells or aortic endothelial cells (16, 33). Du et al. (16) suggested that the initial insult exerted by hyperglycemia is increasing mitochondrial superoxide production. Oxidative stress would inhibit glyceraldehyde-3-phosphate dehydrogenase (GAPDH) activity, which in turn would stimulate flux via the HSP by blocking the flow of F-6-P via glycolysis. The increased UDP-GlcNAc production would cause the enhanced *O*-GlcNAc modification of Sp1 and the ensuing events. These hypotheses are elegantly supported by experiments wherein mitochondrial superoxide production was blunted by adding an inhibitor of complex II, an uncoupler of oxidative phosphorylation, or a superoxide dismutase (SOD) mimetic or by overexpressing UCPI or MnSOD. Although GAPDH activity was markedly decreased after cells were incubated in 30 mM glucose compared with 5 mM glucose, the above-mentioned manipulations restored the activity. An inhibitor of GFAT activity, azaserine, was ineffective. However, all of the above-mentioned manipulations, including azaserine, restored the enhanced *O*-GlcNAc modification of Sp1 in cells incubated with high glucose toward normal, as well as correcting the enhanced TGF- β 1 and PAI-1 promoter activity. However, 30 mM glucose no longer stimulated PAI-1 promoter activity when the Sp1 sites were mutated. In subsequent articles, Brownlee (4, 5) has extended this hypothesis by postulating



that the major mechanism of glucose toxicity is increased mitochondrial superoxide production and that this event can account for the diverse manifestations in vascular cells, i.e., increased polyol pathway flux, increased advanced glycation end product formation, activation of PKC, and increased hexosamine flux.

CLINICAL STUDIES

There are a very few clinical studies examining the role of the HSP in insulin resistance. Yki Järvinen et al. (88) reported in 1996 that GFAT activity was increased in muscle biopsies obtained from insulin-resistant patients with type 2 diabetes. Two papers studied the effect of GlcN infusions on insulin responsiveness in humans. In one paper, minimal effects were observed, i.e., blunted insulin-secretory response in response to a glucose load and mildly increased fasting glucose levels (which could represent the known inhibitory effect of GlcN on islet glucokinase), but in neither paper were any effects noted on glucose utilization during a euglycemic insulin clamp or on hepatic glucose production. Thus humans may be less sensitive to the insulin resistance-promoting effect of GlcN than rodents (48, 58). In a prospective study, the effect of strict blood glucose control with intravenous insulin aimed at euglycemia was examined, in severely insulin-resistant, uncontrolled, obese, type 2 diabetic patients, on the concentration of UDP-GlcNAc and UDP-GalNAc in muscle. Patients underwent insulin clamp studies and muscle biopsies at the beginning and at the end of a 28-day treatment period. Insulin resistance improved markedly as demonstrated by a near doubling of the glucose infusion rate during the clamp and by a marked reduction in daily insulin requirements. Concomitantly, UDP-GlcNAc and UDP-GalNAc in muscle increased by ~40%. This likely reflects the improvement in muscle glucose transport; however, it does not support the hypothesis of a simple, positive correlation between the products of the HSP in muscle and insulin resistance in humans, (59).

In a cross-sectional study, 55 patients, 20 with type 2 diabetes and the rest nondiabetic—with or without obesity—candidates for hip replacement, were studied (60). The objective was to determine whether insulin-resistant patients would have increased UDP-HexNAc levels in fat and muscle and whether there would be a correlation between UDP-HexNAc levels and metabolic parameters. The only significant finding was a positive correlation between UDP-HexNAc and circulating FFA and leptin concentrations in adipocytes, but not in muscle. The study does not provide evidence for a role for HSP in insulin resistance in humans, although a case for its proposed nutrient-sensing role in adipocytes can be made.

As to genetic studies, 412 Caucasian nondiabetic, metabolically characterized individuals were screened for expression of two single-nucleotide polymorphisms (SNP) in the 5'-flanking region of GFAT. One of them (-913 G/A) was associated with a significantly higher body mass index, percent body fat, and increased intramyocellular lipid content in males but not in females (82). A recent publication reports that a single-nucleotide polymorphism in intron 10 of the gene expressing O-GlcNAcase is associated with type 2 diabetes in Mexican Americans (41). Intron 10 contains an alternate stop codon and may lead to decreased expression of the 130-kDa isoform, which is predicted to contain the O-GlcNAcase ac-

tivity. The gene is located on chromosome 10q and overlaps a region that has been previously shown to be associated with type two diabetes.

CONCLUSIONS

There is strong evidence supporting a role for the HSP in the physiopathology of the vascular/renal complications of diabetes. The mode of action appears to be transcriptional regulation, likely modulated by O-GlcNAc modification of transcription factors. Proof of the effect has been provided by gene overexpression and deletion experiments in several tissue culture models, although its role in vivo will have to be more fully established. The role of the HSP as a determinant in the development of insulin resistance is more problematic. Although it is clear that overexpression of GFAT or of OGT can produce insulin resistance in mice, the requirement for increased HSP flux for the establishment of glucose-induced insulin resistance has been questioned. Nevertheless, with the rapidly increasing knowledge of the O-GlcNAc modification of selected proteins and their regulation and the fact that uncontrolled diabetes affects this process, it seems likely that a role for the HSP in the development of the metabolic syndrome and insulin resistance will prevail.

ACKNOWLEDGMENTS

The expert assistance of Katherine A. Robinson in the preparation of this manuscript is gratefully acknowledged.

GRANTS

This work was supported in part by Grant 2R01-DK-02001 from the National Institute of Diabetes and Digestive and Kidney Diseases.

REFERENCES

1. Andreozzi F, D'Alessandris C, Federici M, Laratta E, Del Guerra S, Del Prato S, Marchetti P, Lauro R, Perticone F, and Sesti G. Activation of the hexosamine pathway leads to phosphorylation of insulin receptor substrate-1 on Ser307 and Ser612 and impairs the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin insulin biosynthetic pathway in RIN pancreatic beta-cells. *Endocrinology* 145: 2845–2857, 2004.
2. Ball LE, Berkaw MN, and Buse MG. Comparison of methods for the detection of O-GlcNAc modified proteins (Abstract no. 2602). *Proc 53rd Conf Mass Spectrometry and Allied Topics, San Antonio, TX*, 2005.
3. Baron AD, Zhu JS, Zhu JH, Weldon H, Maianu L, and Garvey WT. Glucosamine induces insulin resistance in vivo by affecting GLUT 4 translocation in skeletal muscle. Implications for glucose toxicity. *J Clin Invest* 96: 2792–2801, 1995.
4. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. *Nature* 414: 813–820, 2001.
5. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. *Diabetes* 54: 1615–1625, 2005.
6. Buse MG and Robinson KA. O-GlcNAcase overexpression does not prevent insulin resistance in 3T3-L1 adipocytes (Abstract). *Diabetes* 54: A-324, 2005.
7. Buse MG, Robinson KA, Gettys TW, McMahon EG, and Gulve EA. Increased activity of the hexosamine synthesis pathway in muscles of insulin-resistant *ob/ob* mice. *Am J Physiol Endocrinol Metab* 272: E1080–E1088, 1997.
8. Buse MG, Robinson KA, Marshall BA, Hresko RC, and Mueckler MM. Enhanced O-GlcNAc protein modification is associated with insulin resistance in GLUT1-overexpressing muscles. *Am J Physiol Endocrinol Metab* 283: E241–E250, 2002.
9. Buse MG, Robinson KA, Marshall BA, and Mueckler M. Differential effects of GLUT1 or GLUT4 overexpression on hexosamine biosynthesis by muscles of transgenic mice. *J Biol Chem* 271: 23197–23202, 1996.

10. **Chen G, Liu P, Thurmond DC, and Elmendorf JS.** Glucosamine-induced insulin resistance is coupled to O-linked glycosylation of Munc18c. *FEBS Lett* 534: 54–60, 2003.
11. **Chen YQ, Su M, Walia RR, Hao Q, Covington JW, and Vaughan DE.** Sp1 sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells. *J Biol Chem* 273: 8225–8231, 1998.
12. **Choi CS, Lee FN, and Youn JH.** Free fatty acids induce peripheral insulin resistance without increasing muscle hexosamine pathway product levels in rats. *Diabetes* 50: 418–424, 2001.
13. **Clark RJ, McDonough PM, Swanson E, Trost SU, Suzuki M, Fukuda M, and Dillmann WH.** Diabetes and the accompanying hyperglycemia impairs cardiomyocyte calcium cycling through increased nuclear O-GlcNAcylation. *J Biol Chem* 278: 44230–44237, 2003.
14. **Comer FI and Hart GW.** Reciprocity between O-GlcNAc and O-phosphate on the carboxyl terminal domain of RNA polymerase II. *Biochemistry* 40: 7845–7852, 2001.
15. **Cooksey RC, Hebert LF, Zhu JH, Wofford P, Garvey WT, and McClain DA.** Mechanism of hexosamine-induced insulin resistance in transgenic mice overexpressing glutamine:fructose-6-phosphate amidotransferase: decreased glucose transporter GLUT4 translocation and reversal by treatment with thiazolidinedione. *Endocrinology* 140: 1151–1157, 1999.
16. **Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, Wu J, and Brownlee M.** Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. *Proc Natl Acad Sci USA* 97: 12222–12226, 2000.
17. **Federici M, Menghini R, Mauriello A, Hribal ML, Ferrelli F, Lauro D, Sbraccia P, Spagnoli LG, Sesti G, and Lauro R.** Insulin-dependent activation of endothelial nitric oxide synthase is impaired by O-linked glycosylation modification of signaling proteins in human coronary endothelial cells. *Circulation* 106: 466–472, 2002.
18. **Gao Y, Miyazaki J, and Hart GW.** The transcription factor PDX-1 is post-translationally modified by O-linked N-acetylglucosamine and this modification is correlated with its DNA binding activity and insulin secretion in min6 beta-cells. *Arch Biochem Biophys* 415: 155–163, 2003.
19. **Gao Y, Wells L, Comer FI, Parker GJ, and Hart GW.** Dynamic O-glycosylation of nuclear and cytosolic proteins: cloning and characterization of a neutral, cytosolic beta-N-acetylglucosaminidase from human brain. *J Biol Chem* 276: 9838–9845, 2001.
20. **Gazdag AC, Wetter TJ, Davidson RT, Robinson KA, Buse MG, Yee AJ, Turcotte LP, and Cartee GD.** Lower calorie intake enhances muscle insulin action and reduces hexosamine levels. *Am J Physiol Regul Integr Comp Physiol* 278: R504–R512, 2000.
21. **Gewinner C, Hart G, Zachara N, Cole R, Beisenherz-Huss C, and Groner B.** The coactivator of transcription CREB-binding protein interacts preferentially with the glycosylated form of Stat5. *J Biol Chem* 279: 3563–3572, 2004.
22. **Gulve EA, Ren JM, Marshall BA, Gao J, Hansen PA, Holloszy JO, and Mueckler M.** Glucose transport activity in skeletal muscles from transgenic mice overexpressing GLUT1. Increased basal transport is associated with a defective response to diverse stimuli that activate GLUT4. *J Biol Chem* 269: 18366–18370, 1994.
23. **Haltiwanger RS, Grove K, and Philipsberg GA.** Modulation of O-linked N-acetylglucosamine levels on nuclear and cytoplasmic proteins in vivo using the peptide O-GlcNAc-beta-N-acetylglucosaminidase inhibitor O-(2-acetamido-2-deoxy-D-glucopyranosylidene)amino-N-phenylcarbamate. *J Biol Chem* 273: 3611–3617, 1998.
24. **Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, Lin J, Bierhaus A, Nawroth P, Hannak D, Neumaier M, Bergfeld R, Giardino I, and Brownlee M.** Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. *Nat Med* 9: 294–299, 2003.
25. **Han DH, Chen MM, and Holloszy JO.** Glucosamine and glucose induce insulin resistance by different mechanisms in rat skeletal muscle. *Am J Physiol Endocrinol Metab* 285: E1267–E1272, 2003.
26. **Han I and Kudlow JE.** Reduced O glycosylation of Sp1 is associated with increased proteasome susceptibility. *Mol Cell Biol* 17: 2550–2558, 1997.
27. **Hawkins M, Angelov I, Liu R, Barzilai N, and Rossetti L.** The tissue concentration of UDP-N-acetylglucosamine modulates the stimulatory effect of insulin on skeletal muscle glucose uptake. *J Biol Chem* 272: 4889–4895, 1997.
28. **Hawkins M, Barzilai N, Liu R, Hu M, Chen W, and Rossetti L.** Role of the glucosamine pathway in fat-induced insulin resistance. *J Clin Invest* 99: 2173–2182, 1997.
29. **Hazel M, Cooksey RC, Jones D, Parker G, Neidigh JL, Witherbee B, Gulve EA, and McClain DA.** Activation of the hexosamine signaling pathway in adipose tissue results in decreased serum adiponectin and skeletal muscle insulin resistance. *Endocrinology* 145: 2118–2128, 2004.
30. **Hebert LF, Daniels MC, Zhou J, Crook ED, Turner RL, Simmons ST, Neidigh JL, Zhu JS, Baron AD, and McClain DA.** Overexpression of glutamine:fructose-6-phosphate amidotransferase in transgenic mice leads to insulin resistance. *J Clin Invest* 98: 930–936, 1996.
31. **Hresko RC, Heimberg H, Chi MM, and Mueckler M.** Glucosamine-induced insulin resistance in 3T3-L1 adipocytes is caused by depletion of intracellular ATP. *J Biol Chem* 273: 20658–20668, 1998.
32. **James DE.** MUNC-ing around with insulin action. *J Clin Invest* 115: 219–221, 2005.
33. **James LR, Fantus IG, Goldberg H, Ly H, and Scholey JW.** Overexpression of GFAT activates PAI-1 promoter in mesangial cells. *Am J Physiol Renal Physiol* 279: F718–F727, 2000.
34. **Kamemura K, Hayes BK, Comer FI, and Hart GW.** Dynamic interplay between O-glycosylation and O-phosphorylation of nucleocytoplasmic proteins: alternative glycosylation/phosphorylation of THR-58, a known mutational hot spot of c-Myc in lymphomas, is regulated by mitogens. *J Biol Chem* 277: 19229–19235, 2002.
35. **Kawanaka K, Han DH, Gao J, Nolte LA, and Holloszy JO.** Development of glucose-induced insulin resistance in muscle requires protein synthesis. *J Biol Chem* 276: 20101–20107, 2001.
36. **Kolm-Litty V, Sauer U, Nerlich A, Lehmann R, and Schleicher ED.** High glucose-induced transforming growth factor beta1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells. *J Clin Invest* 101: 160–169, 1998.
37. **Kreppel LK, Blomberg MA, and Hart GW.** Dynamic glycosylation of nuclear and cytosolic proteins. Cloning and characterization of a unique O-GlcNAc transferase with multiple tetratricopeptide repeats. *J Biol Chem* 272: 9308–9315, 1997.
38. **Kreppel LK and Hart GW.** Regulation of a cytosolic and nuclear O-GlcNAc transferase. Role of the tetratricopeptide repeats. *J Biol Chem* 274: 32015–32022, 1999.
39. **Kurowski TG, Lin Y, Luo Z, Tschlis PN, Buse MG, Heydrick SJ, and Ruderman NB.** Hyperglycemia inhibits insulin activation of Akt/protein kinase B but not phosphatidylinositol 3-kinase in rat skeletal muscle. *Diabetes* 48: 658–663, 1999.
40. **Lamarre-Vincent N, and Hsieh-Wilson LC.** Dynamic glycosylation of the transcription factor CREB: a potential role in gene regulation. *J Am Chem Soc* 125: 6612–6613, 2003.
41. **Lehman DM, Fu DJ, Freeman AB, Hunt KJ, Leach RJ, Johnson-Pais T, Hamlington J, Dyer TD, Arya R, Abboud H, Goring HH, Duggirala R, Blangero J, Konrad RJ, and Stern MP.** A single nucleotide polymorphism in MGEA5 encoding O-GlcNAc-selective N-acetyl-beta-D-glucosaminidase is associated with type 2 diabetes in Mexican Americans. *Diabetes* 54: 1214–1221, 2005.
42. **Lubas WA, Frank DW, Krause M, and Hanover JA.** O-Linked GlcNAc transferase is a conserved nucleocytoplasmic protein containing tetratricopeptide repeats. *J Biol Chem* 272: 9316–9324, 1997.
43. **Marshall S, Bacote V, and Traxinger RR.** Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. *J Biol Chem* 266: 4706–4712, 1991.
44. **McClain DA.** Hexosamines as mediators of nutrient sensing and regulation in diabetes. *J Diabetes Complications* 16: 72–80, 2002.
45. **McClain DA, Lubas WA, Cooksey RC, Hazel M, Parker GJ, Love DC, and Hanover JA.** Altered glycan-dependent signaling induces insulin resistance and hyperleptinemia. *Proc Natl Acad Sci USA* 99: 10695–10699, 2002.
46. **McClain DA, Paterson AJ, Roos MD, Wei X, and Kudlow JE.** Glucose and glucosamine regulate growth factor gene expression in vascular smooth muscle cells. *Proc Natl Acad Sci USA* 89: 8150–8154, 1992.
47. **McGarry JD.** The mitochondrial carnitine palmitoyltransferase system: its broadening role in fuel homeostasis and new insights into its molecular features. *Biochem Soc Trans* 23: 321–324, 1995.
48. **Monauni T, Zenti MG, Cretti A, Daniels MC, Targher G, Caruso B, Caputo M, McClain D, Del Prato S, Giaccari A, Muggeo M, Bonora E, and Bonadonna RC.** Effects of glucosamine infusion on insulin secretion and insulin action in humans. *Diabetes* 49: 926–935, 2000.

49. Nelson BA, Robinson KA, and Buse MG. Defective Akt activation is associated with glucose- but not glucosamine-induced insulin resistance. *Am J Physiol Endocrinol Metab* 282: E497–E506, 2002.
50. Nelson BA, Robinson KA, and Buse MG. High glucose and glucosamine induce insulin resistance via different mechanisms in 3T3-L1 adipocytes. *Diabetes* 49: 981–991, 2000.
51. Nelson BA, Robinson KA, and Buse MG. Insulin acutely regulates Munc18-c subcellular trafficking: altered response in insulin-resistant 3T3-L1 adipocytes. *J Biol Chem* 277: 3809–3812, 2002.
52. Obici S. Hexosamine pathway contribution to insulin resistance-New insights from muscle specific GFAT transgenic. *65th Annu Mtg American Diabetes Association*, 2005.
53. Obici S, Wang J, Chowdury R, Feng Z, Siddhanta U, Morgan K, and Rossetti L. Identification of a biochemical link between energy intake and energy expenditure. *J Clin Invest* 109: 1599–1605, 2002.
54. Parker G, Taylor R, Jones D, and McClain D. Hyperglycemia and inhibition of glycogen synthase in streptozotocin-treated mice: role of O-linked N-acetylglucosamine. *J Biol Chem* 279: 20636–20642, 2004.
55. Parker GJ, Lund KC, Taylor RP, and McClain DA. Insulin resistance of glycogen synthase mediated by O-linked N-acetylglucosamine. *J Biol Chem* 278: 10022–10027, 2003.
56. Patti ME, Virkamaki A, Landaker EJ, Kahn CR, and Yki-Jarvinen H. Activation of the hexosamine pathway by glucosamine in vivo induces insulin resistance of early postreceptor insulin signaling events in skeletal muscle. *Diabetes* 48: 1562–1571, 1999.
57. Pessin JE and Saltiel AR. Signaling pathways in insulin action: molecular targets of insulin resistance. *J Clin Invest* 106: 165–169, 2000.
58. Pouwels MJ, Jacobs JR, Span PN, Lutterman JA, Smits P, and Tack CJ. Short-term glucosamine infusion does not affect insulin sensitivity in humans. *J Clin Endocrinol Metab* 86: 2099–2103, 2001.
59. Pouwels MJ, Span PN, Tack CJ, Olthaar AJ, Sweep CG, van Engelen BG, de Jong JG, Lutterman JA, and Hermus AR. Muscle uridine diphosphate-hexosamines do not decrease despite correction of hyperglycemia-induced insulin resistance in type 2 diabetes. *J Clin Endocrinol Metab* 87: 5179–5184, 2002.
60. Pouwels MJ, Tack CJ, Span PN, Olthaar AJ, Sweep CG, Huvers FC, Lutterman JA, and Hermus AR. Role of hexosamines in insulin resistance and nutrient sensing in human adipose and muscle tissue. *J Clin Endocrinol Metab* 89: 5132–5137, 2004.
61. Ravussin E. Cellular sensors of feast and famine. *J Clin Invest* 109: 1537–1540, 2002.
62. Robinson KA, Sens DA, and Buse MG. Pre-exposure to glucosamine induces insulin resistance of glucose transport and glycogen synthesis in isolated rat skeletal muscles. Study of mechanisms in muscle and in rat-1 fibroblasts overexpressing the human insulin receptor. *Diabetes* 42: 1333–1346, 1993.
63. Robinson KA, Weinstein ML, Lindenmayer GE, and Buse MG. Effects of diabetes and hyperglycemia on the hexosamine synthesis pathway in rat muscle and liver. *Diabetes* 44: 1438–1446, 1995.
64. Robinson KA, Willi SM, Bingel S, and Buse MG. Decreased hexosamine biosynthesis in GH-deficient dwarf rat muscle. Reversal with GH, but not IGF-I, therapy. *Am J Physiol Endocrinol Metab* 276: E435–E442, 1999.
65. Roos MD, Su K, Baker JR, and Kudlow JE. O glycosylation of an Sp1-derived peptide blocks known Sp1 protein interactions. *Mol Cell Biol* 17: 6472–6480, 1997.
66. Rossetti L. Perspective: hexosamines and nutrient sensing. *Endocrinology* 141: 1922–1925, 2000.
67. Rossetti L, Giaccari A, and DeFronzo RA. Glucose toxicity. *Diabetes Care* 13: 610–630, 1990.
68. Rossetti L, Hawkins M, Chen W, Gindi J, and Barzilai N. In vivo glucosamine infusion induces insulin resistance in normoglycemic but not in hyperglycemic conscious rats. *J Clin Invest* 96: 132–140, 1995.
69. Saltiel AR. New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. *Cell* 104: 517–529, 2001.
70. Saltiel AR and Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. *Nature* 414: 799–806, 2001.
71. Savage DB, Petersen KF, and Shulman GI. Mechanisms of insulin resistance in humans and possible links with inflammation. *Hypertension* 45: 828–833, 2005.
72. Shulman GI. Cellular mechanisms of insulin resistance. *J Clin Invest* 106: 171–176, 2000.
73. Thomson MJ, Williams MG, and Frost SC. Development of insulin resistance in 3T3-L1 adipocytes. *J Biol Chem* 272: 7759–7764, 1997.
74. Toleman C, Paterson AJ, Whisenhunt TR, and Kudlow JE. Characterization of the histone acetyltransferase (HAT) domain of a bifunctional protein with activable O-GlcNAcase and HAT activities. *J Biol Chem* 279: 53665–53673, 2004.
75. Van Dam EM, Govers R, and James DE. Akt activation is required at a late stage of insulin-induced GLUT4 translocation to the plasma membrane. *Mol Endocrinol* 19: 1067–1077, 2005.
76. Virkamaki A, and Yki-Jarvinen H. Allosteric regulation of glycogen synthase and hexokinase by glucosamine-6-phosphate during glucosamine-induced insulin resistance in skeletal muscle and heart. *Diabetes* 48: 1101–1107, 1999.
77. Vosseller K, Wells L, Lane MD, and Hart GW. Elevated nucleocytoplasmic glycosylation by O-GlcNAc results in insulin resistance associated with defects in Akt activation in 3T3-L1 adipocytes. *Proc Natl Acad Sci USA* 99: 5313–5318, 2002.
78. Walgren JL, Vincent TS, Schey KL, and Buse MG. High glucose and insulin promote O-GlcNAc modification of proteins, including α -tubulin. *Am J Physiol Endocrinol Metab* 284: E424–E434, 2003.
79. Warram JH, Martin BC, Krolewski AS, Soeldner JS, and Kahn CR. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. *Ann Intern Med* 113: 909–915, 1990.
80. Weigert C, Brodbeck K, Sawadogo M, Haring HU, and Schleicher ED. Upstream stimulatory factor (USF) proteins induce human TGF-beta1 gene activation via the glucose-response element-1013/–1002 in mesangial cells: up-regulation of USF activity by the hexosamine biosynthetic pathway. *J Biol Chem* 279: 15908–15915, 2004.
81. Weigert C, Friess U, Brodbeck K, Haring HU, and Schleicher ED. Glutamine:fructose-6-phosphate aminotransferase enzyme activity is necessary for the induction of TGF-beta1 and fibronectin expression in mesangial cells. *Diabetologia* 46: 852–855, 2003.
82. Weigert C, Thamer C, Brodbeck K, Guirguis A, Machicao F, Machann J, Schick F, Stumvoll M, Fritsche A, Haring HU, and Schleicher ED. The –913 G/A glutamine:fructose-6-phosphate aminotransferase gene polymorphism is associated with measures of obesity and intramyocellular lipid content in nondiabetic subjects. *J Clin Endocrinol Metab* 90: 1639–1643, 2005.
83. Wells L, Gao Y, Mahoney JA, Vosseller K, Chen C, Rosen A, and Hart GW. Dynamic O-glycosylation of nuclear and cytosolic proteins: further characterization of the nucleocytoplasmic beta-N-acetylglucosaminidase, O-GlcNAcase. *J Biol Chem* 277: 1755–1761, 2002.
84. Wells L, Kreppel LK, Comer FI, Wadzinski BE, and Hart GW. O-GlcNAc transferase is in a functional complex with protein phosphatase 1 catalytic subunits. *J Biol Chem* 279: 38466–38470, 2004.
85. Wells L, Vosseller K, and Hart GW. Glycosylation of nucleocytoplasmic proteins: signal transduction and O-GlcNAc. *Science* 291: 2376–2378, 2001.
86. Yang X, Su K, Roos MD, Chang Q, Paterson AJ, and Kudlow JE. O-linkage of N-acetylglucosamine to Sp1 activation domain inhibits its transcriptional capability. *Proc Natl Acad Sci USA* 98: 6611–6616, 2001.
87. Yang X, Zhang F, and Kudlow JE. Recruitment of O-GlcNAc transferase to promoters by corepressor mSin3A: coupling protein O-GlcNAcylation to transcriptional repression. *Cell* 110: 69–80, 2002.
88. Yki-Jarvinen H, Daniels MC, Virkamaki A, Makimattila S, DeFronzo RA, and McClain D. Increased glutamine:fructose-6-phosphate amidotransferase activity in skeletal muscle of patients with NIDDM. *Diabetes* 45: 302–307, 1996.
89. Yki-Jarvinen H, Helve E, and Koivisto VA. Hyperglycemia decreases glucose uptake in type I diabetes. *Diabetes* 36: 892–896, 1987.
90. Yki-Jarvinen H, Virkamaki A, Daniels MC, McClain D, and Gottschalk WK. Insulin and glucosamine infusions increase O-linked N-acetylglucosamine in skeletal muscle proteins in vivo. *Metabolism* 47: 449–455, 1998.
91. Zimmet P, Alberti KG, and Shaw J. Global and societal implications of the diabetes epidemic. *Nature* 414: 782–787, 2001.
92. Ziyadeh FN, Sharma K, Erickson M, and Wolf G. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta. *J Clin Invest* 93: 536–542, 1994.